Market news

Genmab A/S (NASDAQ:GMAB) expects a pivotal fourth quarter, with Phase III readouts planned for three late-stage oncology programs that the company views as potential first-in-class opportunities, according to Andrew Carlsen, the company’s vice president and head of investor relations. Carlsen said

Tipranks Press Release.

The consensus analyst Price Target fair value for Genmab has been adjusted to DKK 2,303.24 from DKK 2,453.79, pointing to a slightly lower central target level for the stock. Analysts link this change to a balance of confidence in Genmab’s pipeline, including Epkinly and other key assets, and caution around concentration risks, clinical assumptions and the impact of the reported $3.6b Darzalex patent cliff. As you read on, you will see how these moving pieces shape the evolving analyst...

Company Announcement COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,011 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 4,409 shares at DKK 1,334.50,1,464 shares at DKK 1,362.50,20,270 shares at DKK 1,615.00, and1,868 shares at DK

Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary General Meeting to be held on Wednesday, October 7, 2026, at 3:00 PM CEST at Genmab's offices, Carl Jacobsens Vej 30, 2500 Valby, Denmark. The notice for the Extraordinary General Meeting, including Appendix 1: Shareholder Letter, is attached. Shareholders are encouraged to visit Genmab’s website at Gen

Genmab A/S (NASDAQ:GMAB) boosted its full-year 2026 revenue guidance to a range of $4.325 billion to $4.525 billion, up from its previous outlook of $4.065 billion to $4.395 billion. The upward revision underscores the strong commercial momentum across the company’s royalty streams and proprietary portfolio. For the first half of 2026, GMAB reported total revenue […]

Media ReleaseCOPENHAGEN, Denmark; August 25, 2026Genmab A/S (Nasdaq: GMAB) announced today that members of its Executive Committee will participate in fireside chats at the following investor conferences in September 2026: Wells Fargo 21st Annual Healthcare Conference in Boston on September 9, 2026, 3:00 PM EDT24th Annual Morgan Stanley Global Healthcare Conference in New York City on September 15, 2026, 8:30 AM EDTBank of America Global Healthcare Conference in London on September 22, 2026, 10:

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator’s choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United […]

Detailed price information for Genmab A/S ADR (GMAB-Q) from The Globe and Mail including charting and trades.

Detailed price information for Ataibeckley Inc (ATAI-Q) from The Globe and Mail including charting and trades.

With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market even opens.

Company Announcement COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 4,702 shares at DKK 1,334.50,2,069 shares at DKK 1,362.50, and17,821 shares at DKK 1,615.00. Proceeds to the Com

Tipranks Press Release.

Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.

Detailed price information for Genmab A/S ADR (GMAB-Q) from The Globe and Mail including charting and trades.

Revenue guidance raised to $4.3B–$4.5B as non-DARZALEX products drive half of growth.

Genmab AS (GMAB) raises 2026 guidance on robust EPKINLY sales and promising late-stage data, while navigating competitive pressures in key oncology markets.

Genmab A/S (NASDAQ:GMAB) reported first-half 2026 revenue growth of 25% year over year and raised its full-year financial outlook, citing continued momentum from DARZALEX, EPKINLY and the broader portfolio. The company also outlined upcoming late-stage trial readouts and announced two new Phase III

Investing.com -- Genmab shares jumped over 8% on Friday, a day after the Danish biotech beat second-quarter expectations and raised its 2026 sales and profit outlook, while confirming a critical bispecific-antibody drug trial readout due in the fourth quarter would be an early look at the data rather than a final one.

August 6, 2026 Copenhagen, Denmark; Interim Report for the Six Months Ended June 30, 2026 Highlights Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant improvement in progression-free survivalGenmab revenue increased 25% compared to the first six months of 2025, to $2,051 millionGenmab 2026 financial guidance updated “The second quarter of 2026 delivered cl

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Detailed price information for Genmab A/S ADR (GMAB-Q) from The Globe and Mail including charting and trades.

Detailed price information for Genmab A/S ADR (GMAB-Q) from The Globe and Mail including charting and trades.

Media Release COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026 Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE® DLBCL-1 trial and was not met Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody®-CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, compared with investigato

Company Announcement Net sales of DARZALEX® in the second quarter of 2026 totaled USD 4,207 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 15, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as repor

Detailed price information for Genmab A/S ADR (GMAB-Q) from The Globe and Mail including charting and trades.

Media ReleaseCOPENHAGEN, Denmark; July 6, 2026 TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of follicular lymphoma in the second-line setting, offering a chemotherapy-free option In the Phase 3 EPCORE® FL-1 trial, fixed-duration TEPKINLY + R2 demonstrated significantly superior progression-free survival and overall response rates compared to R2, with approximately three out of four patients achiev